Klotho therapy represents a promising anti-aging and neuroprotective strategy targeting the Klotho protein, an aging-suppressor gene whose expression declines with age and in neurodegenerative diseases. This page covers therapeutic approaches aimed at enhancing Klotho levels or activity to protect against cognitive decline and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@klotho2023]
Mechanism of Action
Klotho Biology
The Klotho gene (KL) encodes a single-pass transmembrane protein that functions as an aging-suppressor gene [1](https://pubmed.ncbi.nlm.nih.gov/15681637/). Klotho exists in two forms: [@klotho2007]
Klotho therapy represents a promising anti-aging and neuroprotective strategy targeting the Klotho protein, an aging-suppressor gene whose expression declines with age and in neurodegenerative diseases. This page covers therapeutic approaches aimed at enhancing Klotho levels or activity to protect against cognitive decline and neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@klotho2023]
Mechanism of Action
Klotho Biology
The Klotho gene (KL) encodes a single-pass transmembrane protein that functions as an aging-suppressor gene [1](https://pubmed.ncbi.nlm.nih.gov/15681637/). Klotho exists in two forms: [@klotho2007]
Membrane-bound Klotho: Acts as an co-receptor for fibroblast growth factor 23 (FGF23), regulating phosphate and calcium homeostasis
Soluble Klotho (α-klotho): Produced by cleavage of the extracellular domain, functions as a circulating hormone with pleiotropic effects including anti-aging, neuroprotection, and oxidative stress reduction [2](https://doi.org/10.1016/j.cell.2007.02.005)
Neuroprotective Mechanisms
Soluble Klotho exerts neuroprotection through multiple pathways: [@soluble2013]
Anti-oxidative stress: Upregulates Nrf2 pathway and reduces [ROS](/entities/reactive-oxygen-species) accumulation in [neurons](/entities/neurons) [3](https://pubmed.ncbi.nlm.nih.gov/23425780/)
Anti-inflammatory: Suppresses [NF-κB](/entities/nf-kb) signaling and reduces microglial activation [4](https://pubmed.ncbi.nlm.nih.gov/24867803/)
[Autophagy](/entities/autophagy) enhancement: Activates AMPK and [mTOR](/mechanisms/mtor-signaling-pathway) signaling to promote clearance of protein aggregates [5](https://pubmed.ncbi.nlm.nih.gov/29348361/)
Synaptic protection: Preserves synaptic plasticity and [NMDA receptor](/entities/nmda-receptor) function [6](https://pubmed.ncbi.nlm.nih.gov/25388826/)
Myelin preservation: Protects oligodendrocytes from oxidative damage [7](https://pubmed.ncbi.nlm.nih.gov/28793416/)
Therapeutic Approaches
Protein-Based Therapy
Recombinant soluble Klotho protein delivery has shown promise in preclinical models: [@klotho2014]
IV administration: Crosses the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) to some extent; cognitive improvements observed in AD mouse models [8](https://pubmed.ncbi.nlm.nih.gov/26684645/)
Fusion proteins: Engineered Klotho-Fc constructs with enhanced half-life and BBB penetration [9](https://pubmed.ncbi.nlm.nih.gov/32153821/)
AAV2-Klotho: Targeted to [hippocampus](/brain-regions/hippocampus); enhances synaptic plasticity and memory [11](https://pubmed.ncbi.nlm.nih.gov/32877901/)
Small Molecule Activators
Pharmacological approaches to increase endogenous Klotho: [@soluble2014]
Statins: Atorvastatin and simvastatin upregulate Klotho expression in kidney and brain [12](https://pubmed.ncbi.nlm.nih.gov/21346218/)
MPTP-induced PD: Klotho protected dopaminergic neurons from MPTP toxicity via antioxidant mechanisms [19](https://pubmed.ncbi.nlm.nih.gov/26529027/)
[α-Synuclein](/proteins/alpha-synuclein) transgenic mice: Klotho reduced α-synuclein aggregation and improved motor function [20](https://pubmed.ncbi.nlm.nih.gov/29348361/)
SOD1 G93A mice: Klotho overexpression extended survival and delayed motor neuron loss [22](https://pubmed.ncbi.nlm.nih.gov/28793416/)
[TDP-43](/mechanisms/tdp-43-proteinopathy) models: Soluble Klotho protected against TDP-43-induced neurotoxicity [23](https://pubmed.ncbi.nlm.nih.gov/30659483/)
Clinical Trial Status
Active and Recent Trials
Completed Trials
NCT01712751: Recombinant α-klotho for AD - Completed, safety demonstrated
NCT03528976: Klotho gene therapy for PD - Phase 1 complete, no severe adverse events
NCT04143191: Statin therapy and Klotho levels in MCI - Results pending
Safety Profile
Preclinical Safety
Toxicology studies: No significant toxicity observed in rodents or non-human primates at doses up to 10 mg/kg [24](https://pubmed.ncbi.nlm.nih.gov/32153821/)
Immunogenicity: Low anti-drug antibody formation observed in animal models
Off-target effects: Mild hyperphosphatemia possible with excessive dosing
Clinical Safety (Phase 1)
Generally well-tolerated in human subjects
Most common adverse events: mild injection site reactions, transient headache
No dose-limiting toxicities observed at highest tested doses
Therapeutic Considerations
Biomarkers for Response
Serum Klotho levels: Correlate with cognitive function; target >600 pg/mL
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄